Wutah pendapatan taun lumaku: Can-Fite (CANF)

Logo perusahaan publik canfite.com (CANF)

Can-Fite BioPharma (CANF) relies on a stable staff of R&D specialists, selectively engaging only foreign coordinators. Optimized raw material supply chains guarantee high margins for its developments. The creation of a therapy ecosystem via adenosine receptors helps treat psoriasis and liver cancer. The historical year-over-year revenue growth trend over the last 12 months demonstrates sales dynamics, where the value settled at 0.00.

Can-Fite BioPharma (CANF): Wutah pendapatan YoY sajrone 12 wulan kepungkur saka 11.02.2024 nganti 15.11.2026

Can-Fite BioPharma - rincian analitis lan metrik utama (CANF)

- rega saham lan target rega konsensus:
- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Can-Fite BioPharma, Ltd.
Produk merek Can-Fite

Can-Fite BioPharma focuses on developing safe oral medications for the therapy of cancer and liver inflammation. This indicator captures the percentage change in revenue over a rolling year, excluding short-term market fluctuations. The investor analyzes expansion rates to assess the sustainability of the commercialization of developments. Sharp spikes in the relative growth of sales over a 12-month period compared to the previous year may signal rising credit risks. This trend reflects the actual speed of business scaling.

Karo sapa Can-Fite BioPharma saingan

Incyte Pharma - Wutah dodolan YoY sajrone rolas wulan kepungkur|HUTCHMED Corp - Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku Nuvation Bio Inc.|DAWN: Wutah dodolan YoY (TTM)|Tingkat wutah pendapatan YoY sajrone rolas wulan kepungkur Monopar Pharma MNPR|Wutah pendapatan YoY sajrone 12 wulan kepungkur INBX|Wutah pendapatan taun lumaku I-Mab Biopharma IMAB|Wutah pendapatan YoY sajrone 12 wulan kepungkur FENC (Fennec Pharmaceuticals)|HRTX (Heron Therapeutics Inc) - Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Nuvectis Pharma, Inc. - Wutah pendapatan YoY sajrone 12 wulan kepungkur|Owah-owahan pendapatan YoY sajrone 12 wulan kepungkur CHRS (Coherus BioSciences)|Corbus Pharma - Wutah dodolan YoY (TTM)|Dinamika pendapatan YoY sajrone rolas wulan kepungkur CRDF (cardiffoncology.com)|BYSI: Wutah dodolan YoY (TTM)|Wutah pendapatan taun lumaku BioAtla Corp (BCAB)|Wutah dodolan YoY sajrone rolas wulan kepungkur Lixte Biotechnology Holdings, Inc.|CTXR: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY (TTM) CLRB|Wutah dodolan YoY (TTM) BioLineRx Corporation (BLRX)|Wutah dodolan YoY sajrone rolas wulan kepungkur Aprea Therapeutics Inc. APRE|KZIA (kaziatherapeutics.com) - Wutah dodolan taun lumaku|SLXN: Wutah pendapatan YoY sajrone 12 wulan kepungkur|Wutah pendapatan taun lumaku NuCana|CMRX: Wutah dodolan YoY (TTM)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Cyclacel Pharmaceuticals|GTHX (g1therapeutics.com) - Wutah dodolan YoY (TTM)|KRON: Dinamika pendapatan YoY sajrone rolas wulan kepungkur|Wutah dodolan YoY sajrone rolas wulan kepungkur Kintara (KTRA)|Wutah pendapatan YoY sajrone 12 wulan kepungkur Oncternal ONCT|Portage Biotech - Wutah pendapatan YoY sajrone 12 wulan kepungkur